BioSpace News Archive

Simulations Plus, Inc. (Nasdaq: SLP), a premier provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, today announced that Shawn O’Connor, chief executive officer, and Will Frederick, chief financial officer, will be hosting a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Gain Therapeutics, Inc., (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced new pre-clinical data from its Gaucher disease, GM1 gangliosidosis and Morquio B programs.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2020. Record fourth quarter revenue reflects a strong close to 2020: Revenue of $953 million, an increase of 20% compared to the third quarter of 2020 and $0.5 million higher compared to the prior year period

Announced definitive merger agreement with Neos Therapeutics, creating a combined $100 million revenue specialty pharmaceutical company Q2 Consumer Health division revenue reaches an all-time high of $7.9 million Q2 Rx division revenue up 24% sequentially

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has successfully completed a public offering of its securities generating approximately $41.4 million of gross proceeds, prior to deducting underwriting discounts and commissions, and expenses.

Sanara MedTech Inc . Based in Fort Worth, Texas, Sanara MedTech Inc. (NASDAQ:SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, today announced that it intends to offer shares of its common stock in an underwritten public offering.

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted and personalized therapies for rare and difficult to treat cancers, that the Company will report fourth quarter and full year 2020 financial results on Monday, February 22, 2021, after market close.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present at the BMO Biopharma Spotlight Series on Thursday, February 18, 2021 at 11:50 AM ET.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock. All shares are being sold by KKR Genetic Disorder L.P.